IP Library Granted Patent US 10,889,600
Granted Patent B2
US 10,889,600 · App. 16/322,372 · Granted Jan 12, 2021

Boron-containing compounds

Inventors: Franz Amann (Hunzenschwil, CH); Matthew M. Bio (Cambridge, MA); Jonas Bürgler (Hunzenschwil, CH); Yuanqing Fang (Cambridge, MA); David Ford (Cambridge, MA); Daniel McGarry (Malvern, PA)
Assignee: VENATORX PHARMACEUTICALS, INC.
C07F5/025
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,889,600
App. No.
16/322,372
Granted
Jan 12, 2021
Kind
B2
Abstract

Described herein are boron-containing compounds, compositions, and methods for their preparation.

Claims (25)

1. A continuous flow process for making a compound of Formula (III):

wherein

P 1 is a hydroxyl protecting group; and

P 2 is a carboxyl protecting group;

the process comprising:

(a) providing a first continuous flow of a compound of Formula (II) and dichloromethane:

(b) providing a second continuous flow of a base selected from lithium diisopropylamide and 2,2,6,6-tetramethylpiperidinylmagnesium chloride:lithium chloride;

(c) mixing the first continuous flow and the second continuous flow in a mixing chamber to yield a third continuous flow comprising a first reactive intermediate;

(d) collecting the first reactive intermediate into a collection vessel at the output of the third continuous flow;

(e) treating the first reactive intermediate with a Lewis acid; and

(f) warming the collection vessel to provide the compound of Formula (III).

2. The process of claim 1 , wherein the first continuous flow further comprises a coordinating ethereal solvent and the second continuous flow further comprises a coordinating ethereal solvent.

3. The process of claim 1 , wherein the second continuous flow further comprises heptane, ethyl benzene, or a combination thereof.

4. The process of claim 1 , wherein the Lewis acid is provided as a fourth continuous flow further comprising a coordinating ethereal solvent.

5. The process of claim 1 , wherein the water content of the coordinating ethereal solvent is less than about 0.08% (w/w), less than about 0.05% (w/w), or the coordinating ethereal solvent is substantially free of water.

6. The process of claim 1 , wherein the dichloromethane is substantially free of water.

7. The process of claim 1 , wherein the base is substantially free of water.

8. The process of claim 3 , wherein the heptane, ethyl benzene, or a combination thereof is substantially free of water.

9. The process of claim 1 , comprising pre-cooling the first continuous flow to a temperature in the range of about −40° C. to about −10° C. and pre-cooling the second continuous flow to a temperature in the range of about −40° C. to about −10° C.

10. The process of claim 1 , wherein the third continuous flow has a temperature in the range of about −20° C. to about +10° C.

11. The process of claim 1 , comprising maintaining the collection vessel at the output of the third continuous flow at a temperature in the range of about −10° C. to about +10° C.

12. The process of claim 1 , wherein the collection vessel is warmed to room temperature in step (f).

13. The process of claim 1 , wherein the molar ratio of the base to a compound of Formula (II) is in the range of about 1:1 to about 1.5:1, the molar ratio of the dichloromethane to a compound of Formula (II) is in the range of about 5:1 and 7:1, and the molar ratio of the Lewis acid to a compound of Formula (II) is in the range of about 1:1 and 3:1.

14. The process of claim 1 , wherein the base is lithium diisopropylamide and the Lewis acid is ZnCl 2 .

15. The process of claim 1 , wherein P 1 is methyl and P 2 is tert-butyl.

Assignments (9)
CONFIRMATORY LICENSE Recorded Feb 15, 2023
From: VENATORX PHARMACEUTICALS INC
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 062760/0213 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 18, 2020
From: MCGARRY, DANIEL
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 054412/0740 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE'S ADDRESS PREVIOUSLY RECORDED AT REEL: 048243 FRAME: 0098. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Nov 16, 2020
From: CARBOGEN AMCIS AG
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 054438/0248 →
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 048243 FRAME: 0234. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Nov 16, 2020
From: SNAPDRAGON CHEMISTRY, INC.
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 054438/0284 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2019
From: AMANN, FRANZ; BÜRGLER, JONAS
To: CARBOGEN AMCIS AG
Reel/Frame 048242/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2019
From: CARBOGEN AMCIS AG
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 048243/0098 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2019
From: SNAPDRAGON CHEMISTRY, INC.
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 048243/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2019
From: MCGARRY, DANIEL
To: VENATORX PHARMACEUTICALS, INC.
Reel/Frame 048262/0678 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2019
From: BIO, MATTHEW; FANG, YUANQING; FORD, DAVID
To: SNAPDRAGON CHEMISTRY. INC
Reel/Frame 048262/0869 →
Continuity (2)
Provisional Application 62370917 · Aug 4, 2016
Related Publication 20200181174A1 · Jun 11, 2020
Cited By (3)
US 12,187,752 US 12,544,395 US 12,606,573